CA9 and neoplasm: Interestingly, hydantoin salt 3a (an NH-free hydantoin derivative) exhibited much better inhibitory against tumour-associated CA IX compared to all newly developed Furagin derivatives (KIs = 0.35–7.3 μM, average: 2.84 μM).